These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 34545429)
1. [Methotrexate treatment before use of biologics in rheumatoid arthritis : Analysis of guideline compliance]. Pardey N; Zeidler J; Nellenschulte TF; Stahmeyer JT; Hoeper K; Witte T Z Rheumatol; 2023 Sep; 82(7):573-579. PubMed ID: 34545429 [TBL] [Abstract][Full Text] [Related]
2. Risk factors associated with initiation of a biologic disease modifying anti-rheumatic drug in patients with rheumatoid arthritis: A nested case-control study on 34,925 patients. Park EH; Shin A; Ha YJ; Lee YJ; Lee EB; Song YW; Kang EH Joint Bone Spine; 2021 Jan; 88(1):105057. PubMed ID: 32711117 [TBL] [Abstract][Full Text] [Related]
3. Effect of Concomitant Disease-modifying Antirheumatic Drugs and Methotrexate Administration Route on Biologic Treatment Durability in Rheumatoid Arthritis: OBRI Cohort Results. Lau AN; Thorne JC; Movahedi M; Rampakakis E; Cesta A; Li X; Couto S; Sampalis J; Bombardier C; J Rheumatol; 2019 Aug; 46(8):874-886. PubMed ID: 30988121 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness of biologics in Australian patients with rheumatoid arthritis: a large observational study: REAL. Nicholls D; Barrett R; Button P; Truman M; Bird P; Roberts L; Tymms K; Littlejohn G; Griffiths H Intern Med J; 2018 Oct; 48(10):1185-1192. PubMed ID: 29968400 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort. Müller RB; von Kempis J; Haile SR; Schiff MH Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697 [TBL] [Abstract][Full Text] [Related]
6. Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort. Shimizu Y; Tanaka E; Inoue E; Shidara K; Sugimoto N; Seto Y; Nakajima A; Momohara S; Taniguchi A; Yamanaka H Mod Rheumatol; 2018 May; 28(3):461-467. PubMed ID: 28880684 [TBL] [Abstract][Full Text] [Related]
7. [Therapy of rheumatoid arthritis with methotrexate. Claims data analysis of treatment patterns]. Zeidler J; Zeidler H; Graf von der Schulenburg JM Z Rheumatol; 2012 Dec; 71(10):900-7. PubMed ID: 23052404 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Nam JL; Ramiro S; Gaujoux-Viala C; Takase K; Leon-Garcia M; Emery P; Gossec L; Landewe R; Smolen JS; Buch MH Ann Rheum Dis; 2014 Mar; 73(3):516-28. PubMed ID: 24399231 [TBL] [Abstract][Full Text] [Related]
9. Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry. Olsen IC; Lie E; Vasilescu R; Wallenstein G; Strengholt S; Kvien TK Rheumatology (Oxford); 2019 Mar; 58(3):481-491. PubMed ID: 30508189 [TBL] [Abstract][Full Text] [Related]
10. [Guideline-Orientated Prescription of Disease-Modifying Drugs in Patients with Rheumatoid Arthritis - an Analysis Based on Social Health Insurance Claims Data]. Neubauer S; Zeidler H; Linder R; Zeidler J Dtsch Med Wochenschr; 2019 Jun; 144(12):e70-e79. PubMed ID: 30654405 [TBL] [Abstract][Full Text] [Related]
11. Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Uttley L; Bermejo I; Ren S; Martyn-St James M; Wong R; Scott DL; Young A; Stevenson M Pharmacoeconomics; 2018 Sep; 36(9):1063-1072. PubMed ID: 29546668 [TBL] [Abstract][Full Text] [Related]
12. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective. Claxton L; Taylor M; Soonasra A; Bourret JA; Gerber RA J Manag Care Spec Pharm; 2018 Oct; 24(10):1010-1017. PubMed ID: 29897007 [TBL] [Abstract][Full Text] [Related]
13. Predictors of long-term clinical remission in rheumatoid arthritis. Fornaro M; Cacciapaglia F; Lopalco G; Venerito V; Iannone F Eur J Clin Invest; 2021 Feb; 51(2):e13363. PubMed ID: 32725883 [TBL] [Abstract][Full Text] [Related]
14. Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms. Cipriani P; Ruscitti P; Carubbi F; Liakouli V; Giacomelli R Clin Ther; 2014 Mar; 36(3):427-35. PubMed ID: 24612941 [TBL] [Abstract][Full Text] [Related]
15. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438 [TBL] [Abstract][Full Text] [Related]
16. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis. Kim G; Barner JC; Rascati K; Richards K Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313 [TBL] [Abstract][Full Text] [Related]
17. Benefits of Methotrexate Use on Cardiovascular Disease Risk Among Rheumatoid Arthritis Patients Initiating Biologic Disease-modifying Antirheumatic Drugs. Xie F; Chen L; Yun H; Levitan EB; Curtis JR J Rheumatol; 2021 Jun; 48(6):804-812. PubMed ID: 33060309 [TBL] [Abstract][Full Text] [Related]
18. Treatment Strategies in Early Rheumatoid Arthritis Methotrexate Management: Results From a Prospective Cohort. Moura CS; Schieir O; Valois MF; Thorne C; Bartlett SJ; Pope JE; Hitchon CA; Boire G; Haraoui B; Hazlewood GS; Keystone EC; Tin D; Bykerk VP; Bernatsky S; Arthritis Care Res (Hoboken); 2020 Aug; 72(8):1104-1111. PubMed ID: 31112011 [TBL] [Abstract][Full Text] [Related]
19. Higher doses of methotrexate associated with discontinuation of oral glucocorticoids after initiation of biological DMARDs: A retrospective observational study based on data from a Japanese multicenter registry study. Suzuki M; Kojima T; Takahashi N; Asai S; Terabe K; Kaneko A; Hirano Y; Hanabayashi M; Oguchi T; Takagi H; Kanayama Y; Yabe Y; Funahashi K; Fujibayashi T; Tsuboi S; Ito T; Yoshioka Y; Ishikawa H; Sobue Y; Nishiume T; Yokota Y; Ishiguro N Mod Rheumatol; 2021 Jul; 31(4):796-802. PubMed ID: 33492191 [TBL] [Abstract][Full Text] [Related]
20. Utilization of Subcutaneous Methotrexate in Rheumatoid Arthritis Patients After Failure or Intolerance to Oral Methotrexate: A Multicenter Cohort Study. Branco JC; Barcelos A; de Araújo FP; Sequeira G; Cunha I; Patto JV; Oliveira M; Mateus MP; Couto M; Nero P; Pinto P; Monteiro P; Castelão W; Félix J; Ferreira D; Almeida J; Silva MJ Adv Ther; 2016 Jan; 33(1):46-57. PubMed ID: 26724937 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]